Ablynx and Merck Serono enter into an agreement to co-discover and co-develop Nanobodies
Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies against two targets in oncology and immunology and equally share the resulting profits
05-Sep-2008 -
Ablynx announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to co-discover and co-develop Nanobodies® against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of €10 million.
Nanobodies® ...
Ablynx
antibodies
Germany
+5